Departamento de Quimica, Universidade Federal de Sao Carlos-UFSCar, Sao Carlos, SP, Brazil.
Departamento de Quimica, ICEB, Universidade Federal de Ouro Preto - UFOP, Ouro Preto, MG, Brazil.
Anticancer Agents Med Chem. 2021;21(9):1172-1182. doi: 10.2174/1871520620666200824114816.
Breast cancer is one of the most common types among women. Its incidence progressively increases with age, especially after age 50. Platinum compounds are not efficient in the treatment of breast cancer, highlighting the use of other metals for the development of new chemotherapeutic agents.
This paper aims to obtain three new ruthenium compounds that incorporate sulfur amino acids in their structures and to investigate their cytotoxic activity in breast tumor cell lines.
Complexes with general formula [Ru(AA)(dppb)(bipy)] (complexes 1 and 2) or [Ru(AA)(dppb) (bipy)]PF6 (complex 3), where AA = L-cysteinate (1), D-penicillaminate (2), and L-deoxyalliinate (3), dppb = 1,4-bis(diphenylphosphino)butane and 2,2´-bipyridine, were obtained from the cis-[RuCl(dppb)(bipy)] precursor. The cytotoxicity of the complexes on MDA-MB-231 (triple negative human breast cancer); MCF-7 (double positive human breast cancer) and V79 (hamster lung fibroblast) was performed by the MTT (4,5- dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) method. The control agent was the cisplatin, which is a commercially available drug for cancer treatment.
In complexes (1) and (2), the ligands are coordinated to the metal center by nitrogen and sulfur atoms, while in complex (3), coordination is through the oxygen and nitrogen atoms. These suggestions are based on the infrared and 31P{1H} NMR data. For complexes (1) and (2), their X-ray structures were determined confirming this suggestion. The three complexes are stable in a mixture of DMSO (80%) and biological medium (20%) for at least 48h and presented cytotoxicity against the MDA-MB-231 and MCF-7 tumor cells with reasonable selectivity indexes.
Our work demonstrated that ruthenium complexes containing sulfur amino acids, bipyridines and bisphosphines showed cytotoxicity against the MDA-MB-231 and MCF-7 cancer cell lines, in vitro, and that they interact weakly with the DNA (Deoxyribonucleic Acid) and the HSA (Human Serum Albumin) biomolecules.
乳腺癌是女性中最常见的癌症类型之一。其发病率随年龄逐渐增加,尤其是在 50 岁之后。铂类化合物在乳腺癌的治疗中效果不佳,这突出表明需要使用其他金属来开发新的化疗药物。
本文旨在获得三种新的钌化合物,这些化合物在结构中结合了硫氨基酸,并研究它们在乳腺癌肿瘤细胞系中的细胞毒性活性。
采用[Ru(AA)(dppb)(bipy)](复合物 1 和 2)或[Ru(AA)(dppb)(bipy)]PF6(复合物 3)的通式,其中 AA = L-半胱氨酸(1),D-青霉素酸(2)和 L-去氧烯丙氨酸(3),dppb = 1,4-双(二苯基膦)丁烷和 2,2´-联吡啶,由顺式-[RuCl(dppb)(bipy)]前体获得。通过 MTT(4,5-二甲基噻唑-2-基-2,5-二苯基四唑溴盐)法测定复合物对 MDA-MB-231(三阴性人乳腺癌);MCF-7(双阳性人乳腺癌)和 V79(仓鼠肺成纤维细胞)的细胞毒性。对照剂是顺铂,它是一种用于癌症治疗的商业上可用的药物。
在复合物(1)和(2)中,配体通过氮原子和硫原子与金属中心配位,而在复合物(3)中,配位通过氧原子和氮原子进行。这些建议是基于红外和 31P{1H}NMR 数据得出的。对于复合物(1)和(2),其 X 射线结构确定证实了这一建议。在 DMSO(80%)和生物介质(20%)的混合物中,这三种复合物至少在 48 小时内稳定,并对 MDA-MB-231 和 MCF-7 肿瘤细胞表现出细胞毒性,具有合理的选择性指数。
我们的工作表明,含有硫氨基酸、联吡啶和双膦的钌配合物在体外对 MDA-MB-231 和 MCF-7 癌细胞系具有细胞毒性,并且它们与 DNA(脱氧核糖核酸)和 HSA(人血清白蛋白)生物分子的相互作用较弱。